Embecta Corp (EMBC)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $366.02M
Last updated: Nov 17, 2026 at 11:05 AM ET
Embecta Corp (EMBC) P/E Ratio & Valuation History
Embecta (EMBC) trades at 3.1x trailing earnings and 0.3x sales. Its P/E of 3.1x is below its 5-year median of 5.0x. The median P/E across 6 similar companies is 24.8x.
Current Multiples
Its enterprise value is 5.6x its EBITDA. Its free cash flow yield is 46.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 3.1x |
| Forward P/E | N/A |
| Price to sales | 0.3x |
| EV/EBITDA | 5.6x |
| Price to FCF | 2.2x |
| EV/FCF | 9.7x |
| PEG | N/A |
| FCF yield | 46.5% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 3.1x | 5.0x | N/A |
| P/S | 0.3x | 0.8x | N/A |
Valuation History
Over the 4 year ends shown, its P/E ranged from 3.9x in 2025 to 8.2x in 2024. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S |
|---|---|---|---|
| 2025 | $11.88 | 3.9x | 0.6x |
| 2024 | $20.65 | 8.2x | 1.1x |
| 2023 | $18.93 | 7.2x | 1.0x |
| 2022 | $25.29 | 5.3x | 1.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EMBC
Is EMBC stock overvalued?
GNG's valuation label for EMBC is Undervalued. Its P/E of 3.1x compares with a median of 24.8x across 6 similar companies.
What is EMBC's price to sales ratio?
Embecta has a price to sales ratio of 0.3x.
What is Embecta's average P/E ratio over 5 years?
Embecta's median P/E over the last 5 years is 5.0x, from 50 month-end values through Oct 2026.
EMBC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors